-
Advanced Science from Caiyun Fu's Research Group at Zhejiang Sci-Tech University: A new mechanism for the treatment of colorectal cancer with anti-NK-1R drugs
Time of Update: 2021-11-04
Keywords: NK-1R; endoplasmic reticulum stress; MAPK signaling pathway; chemotherapy resistance; colorectal cancer Professor Fu Caiyun's research team from Zhejiang Sci-Tech University School of Life Sciences and Medicine discovered nerves that are clinically used to treat nausea and vomiting after chemotherapy Kinin receptor 1 (NK-1R) antagonists can induce apoptosis of colorectal cancer cells in vitro and in vivo, and its molecular mechanism is through endoplasmic reticulum stress, ERK signal inactivation, and downstream c-Myc protein degradation.
-
"Parallel" CAR-T is coming!
Time of Update: 2021-11-04
The first generation of CAR-T cells: The structure has only one intracellular signal transduction domain (mainly CD-3ζ or FcRγ), which only express single-chain antibodies on T cells, and target tumor cell surface antigen molecules, but the survival time is short and limited To make it work .
-
Eating nuts adds health benefits!
Time of Update: 2021-11-04
Image source: 123RF researchers pointed out, "Our study found for the first time that eating nuts is associated with a reduced risk of breast cancer recurrence, metastasis, or death .
-
Nature Sub-Journal: Transforming bacteria into a drug delivery system is expected to overcome solid solid tumors
Time of Update: 2021-11-04
The research developed a non-toxic, bacteria-based delivery system-Salmonella, which not only can easily enter cells, but also can specifically target cancer cells to directly deliver proteins (drugs) without affecting healthy cells .
-
Professor Wang Yu: Current status of transplantation and application of new drugs in ALL patients
Time of Update: 2021-11-04
Although the current new drugs and cell therapies have shown good efficacy in the treatment of ALL, whether these new drugs and new therapies can improve the MRD status after Allo-HSCT and reduce the disease recurrence rate of ALL patients needs more research.
-
In-depth analysis of osimertinib resistance mechanism
Time of Update: 2021-11-04
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
LBA51 Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study.
-
Accurate management of EGFR-positive patients throughout the process
Time of Update: 2021-11-04
With the success of Osimertinib and a generation of TKIs in the head-to-head PK (FLAURA study), Osimertinib was approved for the first-line treatment of EGFR-sensitive mutations, bringing hope to more lung cancer patients .
-
Knowing about Lymphology·The first phase of big coffee gathered, focusing on the improvement of pathological technology, helping to accurately diagnose lymphoma
Time of Update: 2021-11-04
Zhang Yan: The classic quotations of pathology technology from obtaining materials to staining diagnosis: Do a good job in the quality control of the handover (error-prone) link, and achieve full responsibility to the person (the video is longer, it is recommended to watch under WiFi conditions) The sample processing of Yimaitong includes There are six processes of pretreatment, fixation, dehydration, embedding, slicing and dyeing.
-
How effective is enzalutamide in the real world?
Time of Update: 2021-11-04
Special report (1): Professor Zhu Yaofeng from Qilu Hospital of Shandong University in the field of mCRPC reported on the real-world data of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) before chemotherapy at the ASCO GU conference in 2020, and PSA The impact of the level on the prognosis of prostate cancer patients .
-
The survival period is expected to be extended by nearly 1 year! Don’t forget to do this after you have lung cancer
Time of Update: 2021-11-04
According to a study published in Chest, the official journal of the American College of Physicians (ACCP), people who quit smoking after a diagnosis of non-small cell lung cancer (NSCLC) prolonged their lifespan by nearly one year compared to those who continued to smoke .
-
Prof. Caicun Zhou: Significantly prolong PFS, and Shuglizumab brings new first-line treatment options for metastatic NSCLC
Time of Update: 2021-11-04
At this conference, the main researcher of GEMSTONE-302, Professor Zhou Caicun of Shanghai Pulmonary Hospital affiliated to Tongji University, shared the first-line treatment of metastatic non-small cell lung cancer with suglizumab or placebo combined with platinum chemotherapy in the form of an oral report (NSCLC) randomized, double-blind, phase III GEMSTONE-302 study results (abstract number: MA13.
-
Prof. Cheng Zhang: Application of CAR-T Therapy in HSCT The 16th National Leukemia and Lymphoma Conference
Time of Update: 2021-11-04
In the study of the graft-versus-host disease (GVHD) animal model of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in mice, it was found that CAR-T cells from the donor were returned to the recipient's body on day 01, which has enhanced transplantation.
-
This factor may affect the efficacy of immunotherapy?
Time of Update: 2021-11-04
During this period, the "Medical Oncology Channel" set up a special site for famous doctors Kung Fu tea, and invited the chairman of the conference-Professor Zhang Xin, Zhongshan Hospital, Fudan University Discussed and shared issues related to intestinal flora and lung cancer immunotherapy .
-
Enzalutamide vs. Kalutamide: Who can bring more benefits to patients with nmCRPC?
Time of Update: 2021-11-04
The results of the study showed that in the nmCRPC subgroup, compared with the bicalutamide group, the median treatment time of patients treated with enzalutamide was significantly longer (17.
-
Science Advances Dalian University of Technology Zhao Weijie/Li Guangzhe/Shao Kun uses ultrasound-driven immune-enhancing molecular machines for tumor treatment
Time of Update: 2021-11-04
On October 20, 2021, Dalian University of Technology Zhao Weijie, Li Guangzhe and Shao Kun joint communication (Wang Liu is the first author) published a study titled "An ultrasound-driven immune-boosting molecular machine for systemic tumor suppression" in Science Advances online The thesis, the research uses a previously unknown ultrasound-driven "molecular machine", DYSP-C34 (abbreviated as C34), which has a variety of attractive features, including preferential tumor accumulation, effective ultrasound-triggered cytotoxicity, and intrinsic immune enhancement .
-
Professor Wang Binliang: Radiotherapy is in the ascendant in soft tissue sarcoma with broad prospects
Time of Update: 2021-11-04
Professor Wang Binliang: At present, adjuvant and neoadjuvant therapies are developing rapidly in soft tissue sarcoma and are in the ascendant .
-
Express significantly slows down the disease progression of breast cancer patients, and the phase 3 results of oral estrogen receptor degrading agents are positive
Time of Update: 2021-11-04
▎Editor of WuXi AppTec Content Team On October 20, 2021, Menarini Group and Radius Health announced that selective estrogen receptor degradant (SERD) elacestrant has obtained positive results in a phase 3 clinical trial .
-
Express about 16 million US dollars to help develop a new generation of CAR-T therapy, the new sharp sword refers to ovarian cancer
Time of Update: 2021-11-04
▎Editor of WuXi AppTec content team On October 21, 2021, Leucid Bio announced the completion of a round A financing of approximately US$16 million to launch its main research CAR-T cell therapy LEU-011 to treat platinum-based chemotherapy resistance Phase 1 clinical trial for ovarian cancer .
-
Professor Zhu Xiaoli: Lunvatinib will be used as soon as possible in the treatment of high tumor burden and mid-stage liver cancer
Time of Update: 2021-11-04
The 2021 updated version of the "Clinical Practice Guidelines for Transarterial Chemoembolization (TACE) Treatment of Hepatocellular Carcinoma in China" has recommended TACE combined with targeted therapy for mid-stage HCC with high tumor burden, and lenvatinib for first-line treatment with tumor burden exceeding Up-to-seven Standard mid-stage liver cancer .
-
Prognostic exploration of adult R/R B-ALL patients who progressed after CD19 CAR-T treatment
Time of Update: 2021-11-04
Therefore, some researchers comprehensively analyzed and described in detail the clinical characteristics, follow-up treatment and prognosis of adult B-ALL patients who have progressed after receiving CD19 CAR-T cell therapy at Memorial Sloan Kettering Cancer Center (MSKCC) .
